Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the effect of seralutinib on improving
exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary
objective for this trial is to determine time to clinical worsening.